No Data
While Hainan Shuangcheng Pharmaceuticals (SZSE:002693) Shareholders Have Made 471% in 3 Years, Increasing Losses Might Now Be Front of Mind as Stock Sheds 12% This Week
Hainan Shuangcheng Pharmaceuticals (002693.SZ): The audit and evaluation work for this trade has not yet been completed.
Grain News November 20th | Hainan Shuangcheng Pharmaceuticals (002693.SZ) announced that the trading price of the company's stocks deviated by more than 20% from November 18, 2024, to November 20, 2024, for three consecutive trading days, indicating abnormal stock trading fluctuations. The company is planning a major asset restructuring, intending to purchase 100% of the shares held by Aura Investments, Win Aiming, and 25 other trading parties through issuing shares and paying cash, and plans to issue shares to no more than 35 specific investors to raise supporting funds. The audit of this transaction,
Shuangcheng Pharmaceutical: Report for the third quarter of 2024
hainan shuangcheng pharmaceuticals (002693.SZ): a net loss of 37.8377 million yuan in the first three quarters.
GeLongHui October 30th | Hainan Shuangcheng Pharmaceuticals (002693.SZ) released the third quarter report for 2024, achieving revenue of 0.127 billion yuan in the first three quarters of the company, a year-on-year decrease of 30.34%; net income attributable to shareholders of the listed company -37.8377 million yuan; net income attributable to shareholders of the listed company excluding non-recurring gains and losses -39.9246 million yuan; basic earnings per share -0.0913 yuan.
Is the strongest main theme of this round of market? Mergers and acquisitions continue to be hot, with the "strongest concept stock" closing limit up for 27 consecutive days.
A new round of peak period.
Skyrocketed! 23 halts in 26 days.
A good memory lasts long.
Here's Why Hainan Shuangcheng Pharmaceuticals (SZSE:002693) Can Afford Some DebtNo Data
No Data
